MacroGenics | MGNX - Operating Expenses


MacroGenics reported $42.87M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Amgen USD 5.69B 6B Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Daiichi Sankyo JPY 483.8B 5.85B Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Genmab DKK 748M 77M Jun/2026
Geron USD 54.46M 15.67M Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck USD 10.75B 5.02B Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Xencor USD 87.82M 5.44M Jun/2026